CHRM2 and breast carcinoma: These results, together with the data obtained in other tumor types (i.e., neuroblastoma, breast cancer, and urothelial cancer) [13,15,40,41], highlight the M2 muscarinic receptor as a new strategic therapeutic target in cancer therapy.